Research ArticleOriginal Article

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhujun Liu, Baohui Han and Kai Li
Cancer Biology & Medicine November 2018, 15 (4) 443-451; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0158

Article Information

vol. 15 no. 4 443-451
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2018.0158
Published By 
Cancer Biology & Medicine
History 
  • Received July 3, 2018
  • Accepted October 30, 2018
  • Published online November 1, 2018.
Copyright & Usage 
Copyright: © 2018, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Jing Wang1,*,
  2. Yizhuo Zhao2,*,
  3. Qiming Wang3,
  4. Li Zhang4,
  5. Jianhua Shi5,
  6. Zhehai Wang6,
  7. Ying Cheng7,
  8. Jianxing He8,
  9. Yuankai Shi9,
  10. Hao Yu10,
  11. Yang Zhao10,
  12. Weiqiang Chen11,
  13. Yi Luo12,
  14. Xiuwen Wang13,
  15. Kejun Nan14,
  16. Faguang Jin15,
  17. Jian Dong16,
  18. Baolan Li17,
  19. Zhujun Liu1,
  20. Baohui Han⇑2 and
  21. Kai Li⇑1
  1. 1Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
  2. 2Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai 230030, China
  3. 3Department of Medical Oncology, Henan Province Tumor Hospital, Zhengzhou 450008, China
  4. 4Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100730 China
  5. 5Department of Medical Oncology, Linyi Cancer Hospital, Linyi 276001, China
  6. 6Department of Internal Medicine, Shandong Cancer Hospital, Jinan 250117, China
  7. 7Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun 130012, China
  8. 8Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  9. 9Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China
  10. 10Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 210029, China
  11. 11Department of Respiratory Medicine, Lanzhou Military General Hospital, Lanzhou 730050, China
  12. 12Department of Head and Neck Oncology, Hunan Cancer Hospital, Changsha 220633, China
  13. 13Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan 250000, China
  14. 14Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
  15. 15Department of Respiratory and Critical Diseases, Tang Du Hospital, Xi'an 710038, China
  16. 16Department of Oncology, Yunnan Cancer Hospital, Kunming 650032, China
  17. 17General Department, Capital Medical University Beijing Chest Hospital, Beijing 101149, China
  1. Correspondence to: Baohui Han and Kai Li, E-mail: xkyyhan{at}gmail.com and likai_fnk{at}l63.com
View Full Text

Cited By...

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords